Evidence map›Paper›PMID 34661146›Full record

ArticleBlood cancer discovery2020

Promiscuous Structural Variants Drive Myeloma Initiation and Progression.

P Leif Bergsagel, W Michael Kuehl

Open access · bronzeAbstract readComment
In one paragraph

Article in Blood cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Molecular genetic aberrations in the pathogenesis of multiple myeloma.Asian biomedicine : research, reviews and news · 2023
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

P Leif BergsagelDepartment of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona.ORCID 0000-0003-1523-7388
W Michael KuehlCenter for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Mayo Clinic in Arizona · USNational Cancer Institute · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
Project 3 - Modeling Proteasome Inhibitor Response and Resistance in Cell Lines and Patient Samples with Single Cell Analysis of SubpopulationsU54CA224018 · NCI · MAYO CLINIC ARIZONA · PI BERGSAGEL, PETER LEIF · 2017 to 2021
$6.0M
Mutations that Distinguish Benign from Malignant Plasma Cell NeoplasamsR01CA195688 · NCI · MAYO CLINIC ARIZONA · PI BERGSAGEL, PETER LEIF · 2016 to 2020
$1.9M
NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA195688NCI NIH HHS U54 CA224018
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34661146
PMCPMC8504774
OpenAlexW3092919740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.